News
Amgen is dealing with the threat of several fast-approaching patent expirations. The drugmaker's dividend streak is ...
Having to take Ozempic or other weight loss drugs can be a real pain in the ass, with users often having to jab themselves ...
The new weight loss drug which is set to give Ozempic and Mounjaro a run for their money, MariTide, is taken on a monthly basis rather than weekly.
Amgen has transitioned into a mature, cash-generating pharma-biotech hybrid. Click here to find out why AMGN stock is a Buy.
By Deena Beasley (Reuters) -People started on a low dose of Amgen's long-acting experimental obesity drug MariTide lost as ...
Amgen's late-stage weight-loss drug MariTide is getting ready to enter the final stages of testing as the company enrolls its ...
Amgen Inc. (NASDAQ:AMGN) is one of the 10 Best Value Stocks to Buy According to Billionaires. On June 23, the company ...
Amgen's long-acting experimental obesity drug MariTide needs to be given at a low starting dose to limit side effects like ...
Amgen plans to proceed with Phase 3 trials, initiating patients on a lower dosage that will gradually increase over an ...
Amgen's weight-loss drug MariTide had a successful Phase 2 trial so the company is expanding development plans to study its use for heart disease and sleep apnea.
Eli Lilly and Novo Nordisk, which already have approved GLP-1 weight loss drugs that are raking in billions of revenues, have ...
MariTide helped participants lose up to 20% of their body weight in a year-long trial. But it could be years before the new ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results